Abstract
In this study, we analyzed three groups of patients: those receiving a fixed-dose regimen of amlodipine 5 mg/atorvastatin 10 mg (Caduet 10), those receiving a fixed-dose regimen of amlodipine 5 mg/atorvastatin 20 mg (Caduet 20), and those receiving a free-combination regimen. We obtained data from the National Health Insurance Research Database (NHIRD) of Taiwan from January 1, 2016, to December 31, 2019, to conduct our analysis. After excluding some patients, we included 9,095 eligible patients for further analysis, including 3,313 patients in the Caduet 10 group and 2,658 patients in the Caduet 20 group. The primary endpoint of our study was major adverse cardiovascular events. We found that each component of the primary endpoint was significantly lower in the Caduet 20 group compared to the other two groups (Figure). Additionally, the incidence of newly diagnosed diabetes mellitus (DM) was significantly lower in the Caduet 10 group than in the other two groups . This finding is consistent with previous studies indicating that a higher statin strength may be associated with a higher incidence of newly onset DM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
